A Phase 4 interventional study of doxycycline and doxycycline in Rosacea, sponsored by CollaGenex Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-12-16.
Sponsored by CollaGenex Pharmaceuticals (part of Galderma Group AG) · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.
Among the 12 studies testing doxycycline in Rosacea, this one is the 8th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 4, and was the 3rd registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2007.
This study's enrollment of 91 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 150 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 7 most frequent:
This study is registered under CollaGenex Pharmaceuticals, one of the names counted as Galderma Group AG. Under that name alone:
CollaGenex Pharmaceuticals is the lead sponsor of 3 studies on the registry; none are open to participants now.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2007, is one of 9 in phase 4, and was the 4th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
1 of the studies testing doxycycline in Rosacea that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%
Compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vibramycin plus metronidazole
Drug: doxycycline
Oracea® delayed release plus metronidazole
Drug: doxycycline
COL-101, QD plus metronidazole
Also known as: Vibramycin, 100 mg, QD plus metornidazole
40 mg with metronidazole QD
Also known as: Oracea® 40 mg plus metronidazole
Change in total lesion count from Baseline at the study endpoint
Time frame: 16 weeks
Change in Investigator's Global Assessment from Baseline at the study endpoint
Time frame: 16 weeks
Change in Clinician's Erythema Assessment score from Baseline at the study endpoint
Time frame: 16 weeks
Change in total lesion count (papules + pustules + nodules) from Baseline at each visit
Time frame: 4 weeks, 8 weeks, 12 weeks
The record gives a start of Mar 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline